NIH R01 · 2025
Inflammasomes - a driver of sexual dimorphism to glioma therapies
ABSTRACT Malignant gliomas remain lethal with available therapies, including immune checkpoint blockade. Tumor cells and glioma-associated microglia/macrophages (GAMMs) collectively activate inflammatory responses in the tumor microenvironment (TME), leading to immune suppression, therapy resistance, tumor progression, and relapse. Hence, targeting the protumorigenic TME inflammation is an attractive approach against gliomas. TME inflammation can be induced by inflammasomes, cytosolic innate immune protein complexes that induce cytokine secretion. The NLRP3 inflammasome is expressed in multiple immune cells, and we have identified a population of NLRP3+IL- + proinflammatory macrophages in…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.